载有硝酸芬替康唑的角膜靶向诺瓦索姆用于眼部念珠菌病的治疗:制备、表征和评估。
Corneal targeted fenticonazole nitrate-loaded novasomes for the management of ocular candidiasis: Preparation, characterization, and assessments.
机构信息
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
出版信息
Drug Deliv. 2022 Dec;29(1):2428-2441. doi: 10.1080/10717544.2022.2103600.
The purpose of this manuscript was to develop and optimize Fenticonazole Nitrate (FTN)-loaded novasomes aiming to enhance drug corneal penetration and to improve its antifungal activity. Ethanol injection was used to formulate FTN-loaded novasomes adopting a central composite design. The researched factors were: stearic acid concentration (g%) (A), span 80: drug ratio (B) and cholesterol amount (mg) (C), and their effects on percent entrapment efficiency (EE%), particle size (PS), poly-dispersity index (PDI), zeta potential (ZP), and drug release after 8 hours (Q8h) were studied. Numerical optimization by Design-Expert® software was employed to select the optimum formula in respect to highest EE%, ZP (as absolute value), and Q8h >80% and lowest PS and PDI. Additional evaluation of the optimum formula was accomplished by short term stability study, effect of gamma sterilization, determination of Minimal Inhibitory Concentration and corneal permeation study. The evaluation of the optimum formula was done to ensure its safety via ocular irritancy and corneal tolerance studies. Also, the efficacy was confirmed through corneal uptake study and susceptibility test. The optimum formula with the highest desirability value (0.738) showed EE% (94.31%), PS (197.05 nm), ZP (-66.95 mV) and Q8h (85.33%). It revealed to be safe, with augmented corneal permeation (527.98 µg/cm) that leads to higher antifungal activity. The above results confirmed the validity of novasomes to improve the corneal permeation and antifungal activity of Fenticonazole Nitrate.
本手稿的目的是开发和优化载硝酸益康唑(FTN)的新星脂质体,旨在增强药物角膜穿透性并提高其抗真菌活性。采用乙醇注入法,通过中心复合设计来制备载 FTN 的新星脂质体。研究的因素包括:硬脂酸浓度(g%)(A)、司盘 80:药物比例(B)和胆固醇量(mg)(C),并研究了它们对包封效率(EE%)、粒径(PS)、多分散指数(PDI)、Zeta 电位(ZP)和 8 小时后药物释放(Q8h)的影响。通过 Design-Expert®软件进行数值优化,选择在 EE%(绝对值)、ZP 最高,Q8h>80%和 PS、PDI 最低的最佳配方。通过短期稳定性研究、γ 射线灭菌效果、最小抑菌浓度测定和角膜渗透研究对最佳配方进行进一步评估。通过眼刺激性和角膜耐受性研究来评估最佳配方的安全性。还通过角膜摄取研究和药敏试验来证实疗效。对最佳配方进行评估,以确保其安全性,通过眼刺激性和角膜耐受性研究来评估其安全性。还通过角膜摄取研究和药敏试验来证实疗效。对最佳配方进行评估,以确保其安全性,通过眼刺激性和角膜耐受性研究来评估其安全性。还通过角膜摄取研究和药敏试验来证实疗效。